Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can’t keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company’s shares sky-high.
Get all the details on this potential blockbuster!

BCT Insider Trading (BriaCell Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$353,169.96
Insider Selling (Last 12 Months): C$0.00

BriaCell Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at BriaCell Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BriaCell Therapeutics Share Price & Price History

Current Price: C$7.24
Price Change: Price Increase of +0.44 (6.47%)
As of 06/24/2021 11:00 AM ET

This chart shows the closing price history over time for BCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can’t keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company’s shares sky-high.
Get all the details on this potential blockbuster!

BriaCell Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2021Gadi LevinSenior OfficerBuy2,000C$5.09C$10,187.762,810
4/23/2021William WilliamsDirectorBuy82,750C$4.14C$342,982.20149,636
See Full Table
Insider Buying at BriaCell Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for BriaCell Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for BriaCell Therapeutics (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Read More on BriaCell Therapeutics

Today's Range

Now: C$7.24
Low: C$7.08
High: C$7.24

50 Day Range

MA: C$4.90
Low: C$3.60
High: C$8.00

52 Week Range

Now: C$7.24
Low: C$3.50
High: C$10.98

Volume

1,400 shs

Average Volume

13,796 shs

Market Capitalization

C$103.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of BriaCell Therapeutics?

BriaCell Therapeutics' top insider investors include:
  1. William Williams (Director)
  2. Gadi Levin (Senior Officer)
The EU Lithium Battery Boom
This Company Made a Lithium Discovery That Could Solve Europe's Lithium Shortage!

That's great news for investors. Discover why HERE.
Get Your Battery Boom Report Now!